Carfilzomib/Rituximab/Dexamethasone for Relapsed/Refractory Waldenström’s Macroglobulinemia


Carfilzomib/Rituximab/Dexamethasone for Relapsed/Refractory Waldenström’s Macroglobulinemia
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Rafael Fonseca, MD (2/14/14)
Treon SP et al. Carfilzomib, rituximab and dexamethasone (CaRD) is highly active and offers a neuropathy sparing approach for proteasome-inhibitor based therapy in Waldenstrom’s macroglobulinemia. Proc ASH 2013;Abstract 757.

Dr Fonseca is Getz Family Professor of Cancer and Chair of the Department of Internal Medicine at the Mayo Clinic Arizona in Scottsdale, Arizona.